Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Obinutuzumab + RO6958688 + RO7122290|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Obinutuzumab||Gazyva||R7159|afutuzumab|GA101|GA-101|RO 5072759||CD20 Antibody 21||Gazyva (obinutuzumab) is a glycoengineered anti-CD20 antibody that binds to CD20 on B-cells, resulting in increased antibody-dependent cellular cytotoxicity and induction of apoptosis, and potentially leading to decreased growth of B-cell tumors (PMID: 20194898, PMID: 21220500). Gazyva (obinutuzumab) is FDA approved in combination with Ambochlorin (chlorambucil) for chronic lymphocytic leukemia and in combination with Treanda (bendamustine) or chemotherapy for follicular lymphoma (FDA.gov).|
|RO6958688||RG7802|Cibisatamab|CEA-TCB|RO-6958688||CD3 Antibody 86||RO6958688 (cibisatamab) is a bispecific antibody that binds to CD3 and human anti-carcinoembryonic antigen (CEA) simultaneously, which may lead to cytotoxic immune response against CEA-positive tumor cells (PMID: 30982469).|
|RO7122290||RO 7122290|RO-7122290||RO7122290 is a fusion protein consisting of a ligand of TNFRS9 fused to a Fab fragment targeting FAP, which may lead to activation of anti-tumor immune response against FAP-expressing tumor cells (Ann Oncol Sep 2020, 31 (Suppl 4), S707).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04826003||Phase Ib/II||Obinutuzumab + RO6958688 + RO7122290||Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment||Recruiting||GBR | ESP | CAN||3|